Real-life use of Rivaroxaban in the Netherlands: data from the  Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.

CONCLUSION: In the Dutch subset of the XANTUS registry, we observed low rates of major bleeding and label-discordant dosing and high persistence rates during one year of follow-up in patients receiving rivaroxaban in routine clinical practice. However, documenting the motivation of novel oral anticoagulant (NOAC) type and dose is essential to study label-discordant prescription, a potential safety paradox and identify patient characteristics to optimise NOAC use and adherence.
PMID: 28674871 [PubMed - as supplied by publisher]

Source: Netherlands Heart Journal - July 3, 2017 Category: Cardiology Authors: Pisters R, van Vugt SPG, Brouwer MA, Elvan A, Ten Holt WL, Zwart PAG, Kirchhof P, Crijns HJGM, Hemels MEW Tags: Neth Heart J Source Type: research